BiVictriX Therapeutics PLC's (AIM:BVX, OTC:BVTXF) boss said 2023 had been a remarkable year for the cancer drug developer, especially BVX001, its lead treatment for Acute Myeloid Leukaemia.
Tiffany Thorn, chief executive, said: "We have made considerable progress with BVX001, the company's lead bispecific ADC [targeted cancer drug], towards getting this asset ready for the clinic, identifying our route to market and attracting the support of globally recognised KOLs [opinion leaders] in the AML space.
“Post period end, we have continued to make significant progress across our wider portfolio, and we are on track to nominate a clinical candidate for our solid tumour programme, BVX002, and further expand our IP portfolio.”
BiVictriX ended the year to December 2023 with a cash balance of £3.3 million following a fundraising in August.
R&D expenditure for the year was £2.0 million with a loss after tax in the year of £2.5 million.